Advertisement
Screener

IMMUNOVANT, INC. (IMVT) Graph

IMVT Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development (m); Operating expenses $160.32M; Income tax $0.00; Net income -$153.22M.
  • 2026-03-31: Research and development (m); Operating expenses $159.55M*; Income tax -$2.84M*; Net income -$147.86M*.
  • 2025-12-31: Research and development (m); Operating expenses $114.36M; Income tax $1.55M; Net income -$110.64M.
  • 2025-09-30: Research and development (m); Operating expenses $131.76M; Income tax $594.00K; Net income -$126.50M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$160.32M$0.00-$153.22M
2026-03-31(m)$159.55M*-$2.84M*-$147.86M*
2025-12-31(m)$114.36M$1.55M-$110.64M
2025-09-30(m)$131.76M$594.00K-$126.50M
2025-06-30(m)$127.22M$913.00K-$120.61M
2024-12-31(m)$114.30M$152.00K-$111.12M
2024-09-30(m)$115.74M$78.00K-$109.12M
2024-06-30(m)$94.28M$77.00K-$87.15M
2023-12-31(m)$61.55M-$108.00K-$51.42M
2023-09-30(m)$61.80M$454.00K-$58.66M
2023-06-30(m)$78.48M-$11.00K-$73.94M
2022-12-31(m)$64.03M$387.00K-$63.23M
2022-09-30$37.74M$49.61M$261.00K-$47.93M
2022-06-30$28.43M$40.38M$352.00K-$40.37M
2022-03-31$31.99M*(m)(m)(m)
2021-12-31$29.76M$41.27M$0.00-$41.38M
2021-09-30$21.36M$37.65M-$31.00K-$37.70M
2021-06-30$18.70M$29.89M-$41.00K-$30.47M
2020-12-31$21.09M$31.64M-$367.00K-$31.78M
2020-09-30$11.98M$20.97M$40.00K-$20.79M
2020-06-30$16.92M$26.59M$48.00K-$26.71M
2019-12-31$4.95M$11.04M$100.00K-$11.30M
2019-09-30$10.33M$14.49M$33.00K-$14.48M
2019-06-30$18.48M$20.06M$23.00K-$20.06M
2019-03-31(m)(m)(m)-$450.00
2018-12-31$7.68M$8.88M$8.00K-$8.85M
2018-09-30(m)(m)(m)-$6.35M
2018-07-06(m)(m)(m)-$4.37M
2018-06-30(m)(m)(m)-$4.37M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$258.99M$1.51M-$247.12M
2024-09-30(m)$210.02M$156.00K-$196.27M
2023-09-30(m)$140.28M$443.00K-$132.60M
2022-09-30$66.17M$89.99M$613.00K-$88.30M
2021-09-30$40.07M$67.53M-$72.00K-$68.17M
2020-09-30$28.90M$47.56M$88.00K-$47.50M
2019-09-30$28.81M$34.55M$56.00K-$34.54M
2019-06-30(m)$67.74K$66.47K$182.30K

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$373.35M$3.06M-$357.75M
2024-12-31(m)$324.33M$308.00K-$307.39M
2023-12-31(m)$201.83M$335.00K-$184.02M
2022-12-31(m)$154.02M$1.00M-$151.53M
2021-12-31$69.82M$108.81M-$72.00K-$109.56M
2020-12-31$49.99M$79.20M-$279.00K-$79.27M
2019-12-31$33.76M$45.59M$156.00K-$45.84M
2019-09-30(m)$462.90K$204.76K$307.39K
2019-03-31(m)(m)(m)-$24.23M
2018-12-31$17.76M$19.49M$12.00K-$19.57M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-03-31(m)$532.90M$215.00K-$505.61M
2025-03-31(m)$438.15M$891.00K-$413.84M
2024-03-31(m)$282.71M$567.00K-$259.34M
2023-03-31(m)$218.28M$9.00K-$210.96M
2022-03-31$101.81M$156.03M-$84.00K-$156.73M
2021-03-31$68.60M$108.12M-$358.00K-$107.43M
2020-03-31$47.93M$66.08M$97.00K-$66.39M
2019-03-31$25.73M$28.43M$19.00K-$28.60M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56